Τίτλος:
Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aims High-density lipoprotein (HDL) function may be altered in patients with chronic disease, transforming the particle from a beneficial vasoprotective molecule to a noxious pro-inflammatory equivalent. Adolescents with Type 1 diabetes often have elevated HDL, but its vasoprotective properties and relationship to endothelial function have not been assessed. Methods and results Seventy adolescents with Type 1 diabetes (age 10-17 years) and 30 age-matched healthy controls supplied urine samples for the measurement of early renal dysfunction (albumin:creatinine ratio; ACR), blood samples for the assessment of cardiovascular risk factors (lipid profiles, HDL functionality, glycaemic control, and inflammatory risk score), and had their conduit artery endothelial function tested using flow-mediated dilation (FMD). HDL-c levels (1.69 ± 0.41 vs. 1.44 ± 0.29mmol/L; P < 0.001), and glycated haemoglobin (HbA1c) (8.4 ± 1.2 vs. 5.4 ± 0.2%; P < 0.001) were increased in all patients compared with controls. However, increased inflammation and HDL dysfunction were evident only in patients who also had evidence of early renal dysfunction (mean ± standard deviation for high-ACR vs. low-ACR and healthy controls: inflammatory risk score 11.3 ± 2.5 vs. 9.5 ± 2.4 and 9.2 ± 2.4, P < 0.01; HDL-mediated nitric-oxide bioavailability 38.0 ± 8.9 vs. 33.3 ± 7.3 and 25.0 ± 7.7%, P < 0.001; HDL-mediated superoxide production 3.71 ± 3.57 vs. 2.11 ± 3.49 and 1.91 ± 2.47nmol O2 per 250 000 cells, P < 0.05). Endothelial function (FMD) was impaired only in those who had both a high inflammatory risk score and high levels of HDL-c (P < 0.05). Conclusion Increased levels of HDL-c commonly observed in individuals with Type 1 diabetes may be detrimental to endothelial function when accompanied by renal dysfunction and chronic inflammation. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
Συγγραφείς:
Chiesa, S.T.
Charakida, M.
McLoughlin, E.
Nguyen, H.C.
Georgiopoulos, G.
Motran, L.
Elia, Y.
Loredana Marcovecchio, M.
Dunger, D.B.
Neil Dalton, R.
Daneman, D.
Sochett, E.
Mahmud, F.H.
Deanfield, J.E.
Περιοδικό:
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
Εκδότης:
Oxford University Press
Λέξεις-κλειδιά:
hemoglobin A1c; high density lipoprotein; high density lipoprotein cholesterol; nitric oxide; biological marker; high density lipoprotein, adolescent; Article; blood sampling; cardiovascular risk; child; controlled study; disease association; endothelial dysfunction; female; glycemic control; hemoglobin blood level; human; inflammation; insulin dependent diabetes mellitus; kidney failure; lipid fingerprinting; major clinical study; male; microalbuminuria; priority journal; risk factor; scoring system; urine sampling; blood; case control study; chronic disease; complication; hyperlipidemia; inflammation; insulin dependent diabetes mellitus; kidney failure; pathophysiology; vascular endothelium, Adolescent; Biomarkers; Case-Control Studies; Child; Chronic Disease; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Humans; Hyperlipidemias; Inflammation; Lipoproteins, HDL; Male; Renal Insufficiency
DOI:
10.1093/eurheartj/ehz114
